Skip to main content

News and blog posts

17
Aug 2021

Applications for 2022/23 High Cost Device List are open in England

In late July 2021, NHS England opened a call for applications to the High Cost Device List (HCDL) changes for the 2022/23 National Tariff Payment System. The completed application form should be submitted via email by September 30, 2021. HCDL is an add-on reimbursement for medical devices and in-vitro diagnostic tests, so the amount is paid in addition to the payment for regular care.
16
Aug 2021

Applications for coverage with evidence development programs released in France

On July 29, 2021, the French Ministry of Solidarity and Health published the instruction related to the 2021 application for coverage with evidence development programs. In the instruction, the specific fields of research, the application procedures, and the deadlines for applications for different types of projects (PHRC, PRME, PREPS, PRT) are specified.
13
Aug 2021

Med Tech-related technology assessments and clinical guidelines from NICE in July 2021

In July 2021, the National Institute for Health and Care Excellence (NICE) published one new Interventional Procedure Guidance (inducing and maintaining normothermia using temperature modulation devices to improve outcomes after stroke or subarachnoid hemorrhage) and four new Medtech Innovation Briefings (HealthVCF for detecting vertebral compression fractures on CT scans, trublood-prostate for triaging and diagnosing people with prostate cancer symptoms, AI technologies for detecting diabetic retinopathy, and Acumen IQ sensor for predicting hypotension risk).
12
Aug 2021

2022 version of the Swiss CHOP code nomenclature published

On July 30, 2021, the Swiss Federal Statistics Office (UFS) published the 2022 version of the procedure code (CHOP) nomenclature in the German language. The newly introduced codes concern various technology groups, such as cardiovascular, gastrointestinal, neurology, interventional radiology, orthopedics, gynecology, and others.
10
Aug 2021

New med tech-related decision support documents published in Austria

In July 2021, the Austrian Institute for Health Technology Assessment (AIHTA) published six new decision support documents and one update to a previous decision support document. The assessed topics included percutaneous left ventricular assist devices, liposuction for surgical therapy of lipoedema, triphasic biomaterial for augmentation of the osteoporotic femoral neck, endoscopic plication therapy in patients with gastroesophageal reflux disease (GERD), allogenic bone screw Shark Screw® in patients with hallux valgus or scaphoid fractures/pseudarthroses, and surgical interventions for the treatment of benign prostatic hyperplasia. The updated decision support document concerned implantable bulking agents for fecal incontinence.
09
Aug 2021

A new approach to prioritizing requests for NICE Scientific Advice

On July 16, 2021, NICE announced a new approach to prioritizing requests for NICE Scientific Advice. Because of the increased engagement, the waiting time for new scientific advice projects is currently several months. To address this, from December 2021, NICE will reserve priority slots in the work plan for companies developing high-priority technologies for the NHS.
06
Aug 2021

TLV assessed Oncotype DX and ProSigna tests for early breast cancer detection in July 2021

In July 2021, the Dental and Pharmaceutical Benefits Agency released two completed health economic evaluations on the cost-effectiveness of the Oncotype DX and ProSigna tests. The evaluation was performed at the request of the Medical Technology Product (MTP) Council. The cost per quality-adjusted life-years for ProSigna is estimated to be 207,000 SEK compared to the stand-alone clinical pathology assessment. The analysis indicates that the use of Oncotype DX provides greater benefit than the alternative, also at a lower cost.
03
Aug 2021

MTRC released a 2021 update of its syndicated report on innovation funding schemes in Europe

A syndicated report (135 pages) reviews details of innovation funding and coverage with evidence development schemes in Europe, including Austria, Belgium, England, France, Germany, the Netherlands, and Switzerland. For each scheme, information about objective, inclusion criteria, applicant, stakeholders involved, clinical and economic evidence requirements, and statistics (including at least 2019-2020 data; but for most schemes – statistics for multiple years) is included.
03
Aug 2021

2021-2022 Romanian Framework Contract entered into force

On July 1, 2021, the updated Framework Contract that defines the social health insurance benefit package in Romania entered into force. The Framework Contract defines the SHI benefits package, the conditions for providing services and payments. The updated Framework Contract will be valid for the years 2021-2022.